Showing results (171-180 of 211) with videos related to
Sort By:
Pageof 22
Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysisLi-Yang Chen, Miguel A Molina-Vila, Sheng-Yuan Ruan, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 14, 2017
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitorsBin-Chi Liao, Ya-Ying Bai, Jih-Hsiang Lee, et al.JTO Clinical and Research Reports|September 30, 2021
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in <i>EGFR</i> T790M-Positive NSCLCBin-Chi Liao, Wei-Hsun Hsu, Jih-Hsiang Lee, et al.Cancer Research|September 17, 2008
Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1Huei-Wen Chen, Jen-Yi Lee, Ji-Ying Huang, et al.Lung Cancer (Amsterdam, Netherlands)|November 5, 2013
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopyTzu-Hsiu Tsai, Ching-Yao Yang, Chao-Chi Ho, et al.Journal for Immunotherapy of Cancer|November 27, 2020
Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapyChia-Sing Lu, Ching-Wen Lin, Ya-Hsuan Chang, et al.Disease Models & Mechanisms|January 24, 2025
Patient-derived xenograft models of gastrointestinal stromal tumors provide a ready-to-use platform for translational researchLuna De Sutter, Lore De Cock, Chao-Chi Wang, et al.American Journal of Cancer Research|August 10, 2023
T790M detection rate after first-line combination therapy with bevacizumab and EGFR-TKIs in advanced NSCLC (TERRA Study)Chih-Hsi Scott Kuo, Po-Lan Su, Yu-Feng Wei, et al.Therapeutic Advances in Medical Oncology|January 8, 2024
Primary tumor consolidative therapy improves the outcomes of patients with advanced <i>EGFR</i>-mutant lung adenocarcinoma treated with first-line osimertinibJia-Jun Wu, Jeng-Sen Tseng, Zhe-Rong Zheng, et al.Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|October 3, 2012
Etiology of pulmonary complications of human immunodeficiency virus-1-infected patients in Taiwan in the era of combination antiretroviral therapy: a prospective observational studyKuan-Yeh Lee, Chao-Chi Ho, Dar-Der Ji, et al.Pageof 22